Notification That Annual Report Will Be Submitted Late (nt 10-k)
March 30 2020 - 10:14AM
Edgar (US Regulatory)
|
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
|
SEC FILE NUMBER
000-32363
|
CUSIP NUMBER
13738M103
|
FORM 12b-25
NOTIFICATION OF LATE FILING
☑
Form 10-K ☐ Form 20-F ☐ Form 11-K ☐ Form 10-Q ☐
Form 10-D ☐ Form N-SAR ☐ Form N-CSR
For period ended: December
31, 2019
☐ Transition
Report on Form 10-K
☐ Transition
Report on Form 20-F
☐ Transition
Report on Form 11-K
☐ Transition
Report on Form 10-Q
☐ Transition
Report on Form N-SAR
For the Transition Period
Ended: ____________
Nothing in this form shall be construed
to imply that the Commission has verified any information contained herein.
PART I – REGISTRANT INFORMATION
CANCER CAPITAL CORP.
Full Name of Registrant
2157 S. LINCOLN STREET, SUITE 200
Address of Principal Executive Office
SALT LAKE CITY, UTAH 84106
City, State and Zip Code
PART II – RULES 12b-25(b) AND (c)
If the subject report could not be filed without unreasonable effort
or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed.
|
|
|
|
(a)
|
The
reasons described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;
|
☑
|
(b)
|
The
subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, 11-K or Form N-SAR or Form N-CSR, or
portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly
report or transition report on Form 10-Q, or subject distribution report on Form 10-D, or portion thereof, will be filed on
or before the fifth calendar day following the prescribed due date; and
|
|
(c)
|
The
accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached, if applicable.
|
PART III – NARRATIVE
The Company is unable, without unreasonable effort and expense,
to file the Form 10-K for the period ended December 31, 2019 within the prescribed time period due to its difficulty in obtaining
and completing the financial and other information required for such report.
PART IV – OTHER INFORMATION
(1) Name and telephone
number of person to contact in regards to this notification:
John W. Peters
|
|
801
|
|
323-2395
|
(Name)
|
|
(Area Code)
|
|
(Telephone Number)
|
|
(2)
|
Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of
the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to
file such report(s) been filed? If the answer is no, identify report(s). ☑ Yes ☐ No
|
(3) Is it anticipated that any significant change in results
of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included
in the subject report or portion thereof? ☐ Yes ☑ No
CANCER CAPITAL CORP.
(Name of Registrant as Specified in Charter)
has caused this notification to be signed on its behalf by the undersigned
hereunto duly authorized.
Date: March 30, 2020
|
By: /s/ John W. Peters
John W. Peters
President and Director
Principal Financial Officer
|
Cancer Capital (PK) (USOTC:CNCL)
Historical Stock Chart
From Aug 2024 to Sep 2024
Cancer Capital (PK) (USOTC:CNCL)
Historical Stock Chart
From Sep 2023 to Sep 2024